101 results about "Goblet cell" patented technology

The invention provides a duodenal mucosa adjusting system and method based on pulsed electric field ablation and application of the duodenal mucosa adjusting system and method in diabetes treatment, the duodenal mucosa adjusting system comprises an intelligent control host capable of achieving bidirectional data transmission and an adjustable catheter, and the intelligent control host initializes parameters and adjusts pulse parameters by monitoring impedance data in real time until pulses are interrupted or terminated; periodic ablation is carried out, periodic intervals are used for measuring impedance data, the ablation depth is evaluated according to the impedance change rate, and whether next section ablation is carried out or not is judged till full-area ablation is completed. The far-end ablation adopts a structure of combining fusiform flexible support and annular electrode spiral arrangement to ensure that an ablation field uniformly covers mucous membrane plica of a duodenum bulb part and a descending part; a cell selective ablation mechanism is adopted, the critical electric field intensity is set, K cell electroporation is selectively induced, and meanwhile goblet cells are protected.

Apparatuses, systems and methods are provided for treating pulmonary tissues via delivery of energy, generally characterized by high voltage pulses, to target tissue using a pulmonary tissue modification system (e.g., an energy delivery catheter system). Example pulmonary tissues include, without limitation, those within the respiratory tract, particularly the epithelium (the goblet cells, ciliated pseudostratified columnar epithelial cells, and basal cells), lamina propria, submucosa, submucosal glands, basement membrane, smooth muscle, cartilage, nerves, pathogens resident near or within the tissue, or a combination of any of these. The systems may be used to treat pathogens, such as bacteria and viruses, particularly coronaviruses.

The invention belongs to the technical field of biological medicine, and particularly relates to a construction method of a gastric mucosa intestinal epithelial metaplasm type organ model with goblet cell phenotype. The model is characterized by MUC2 + MUC6 + goblet cells, and histological characteristics of gastric mucosa intestinal metaplasia are more deeply simulated from the aspect of cell phenotype. The construction method comprises the following steps: (1) obtaining a human stomach gland to prepare an organoid; (2) subculturing the organoid; (3) construction of a pCDH-CMV-MCS-EF1-CDX2-Puro overexpression lentiviral vector, and construction of a pCDH- (4) virus packaging; (5) constructing CDX2 overexpression stably transfected cells and organoid; and (6) carrying out gradient differentiation on the CDX2 overexpression organoid to prepare the intestinal metaplasia organoid. According to the invention, the pathological transformation of the cytology level in the gastrointestinal mucosa intestinal epithelial metaplasia process is realized in the in-vitro model for the first time, and a new research model and theoretical guidance are provided for the diagnosis, prevention and individualized precise treatment of precancerous lesions of gastric cancer.

The invention relates to the technical field of biological medicine, in particular to a drug screening model construction method based on airway organs, a model and application. The construction method of the drug screening model of the airway organoid comprises the steps of obtaining 2D airway epithelial cells, culturing the airway organoid, establishing an airway organoid inflammation model and / or establishing an airway organoid mucus secretion / goblet cell metaplasia model. Wherein the model is established according to the culture mode of the airway organ in cooperation with a specific stimulant for proliferation and differentiation. Compared with a traditional animal model, the organ-like model is low in cost and short in construction period, can better simulate the pathological process, can realize airway organ-like culture and establishment of an inflammation model and a mucus secretion / goblet cell metaplasia model at the same time, and has a good application prospect in drug detection of asthma and COPD diseases.

The present invention relates to superoxide dismutase and its use in the prevention or treatment of dry eye. More specifically, the present invention relates to a pharmaceutical composition or a treatment method for preventing or treating dry eye. According to the compositions and methods of the present invention, an increase in the secretion amount selected from tear fluid can be achieved; the tear film rupture time is prolonged; minimizing ocular surface damage; goblet cells in the conjunctiva are protected; the number of immune cells and inflammatory cell factors in cornea and conjunctiva is reduced; reduction of oxidative stress in cornea, conjunctiva and lacrimal gland; and a reduction in corneal epithelial cell apoptosis, thereby being effectively used in the prevention or treatment of dry eye.

The invention belongs to the technical field of health-care food, and particularly relates to a prune exosome, a preparation method thereof and application of the prune exosome in preparation of bowel relaxing products. According to the preparation method of the prune exosome, deep processing is carried out on prune, the prune exosome is extracted from the prune, and miRNA nucleic acid contained in the prune exosome is used for promoting expression of mucoprotein genes in goblet cells and proliferation of beneficial bacteria such as bifidobacteria and lactic acid bacteria; the adverse effect of oxidative stress on intestinal cells and microbial communities is reduced by using the antioxidant activity of the prune exosome, and the effect of relaxing bowel is realized, so that the technical problem that deep processing research of prune is lacked in the prior art is solved.

To provide interventional procedures which are easy to control, match pathophysiologic aberrancies, allow treatment of large surface areas at appropriate depths, and can limit amounts of inflammatory response and remodeling.SOLUTION: Systems and methods are provided for treating pulmonary tissues via delivery of energy to target tissue using a pulmonary tissue modification system (100) such as an energy delivery catheter (102) system. Example pulmonary tissues include the epithelium (goblet cells, ciliated pseudostratified columnar epithelial cells, and basal cells), lamina propria, submucosa, submucosal glands, basement membrane, smooth muscle, cartilage, and / or nerves. The system may be used to treat a variety of pulmonary diseases or pulmonary disorders such as COPD (e.g., chronic bronchitis, emphysema), asthma, interstitial pulmonary fibrosis, cystic fibrosis, bronchiectasis, primary ciliary dyskinesia (PCD), and / or acute bronchitis.SELECTED DRAWING: Figure 5

The present invention relates to a pharmaceutical composition for preventing or treating inflammatory bowel diseases, comprising Lactobacillus murinus as an active ingredient. More specifically, it has been identified that drinking three times a week significantly reduces the length of the large intestine in comparison to other drinking patterns, and it has been identified that by administering Lactobacillus murinus, intestinal inflammation is improved such as with respect to large intestine length restoration and an increase in goblet cell count, and thus the present invention can be variously utilized as a therapeutic agent for inflammatory bowel disease, a health functional food composition and the like.

The present invention relates to an intestinal epithelium model faithfully reproducing the pathophysiological mechanisms observed in vivo in the context of an inflammatory state of the intestinal barrier. The model according to the present invention comprises two compartments separated by a semi-permeable membrane. The first compartment, corresponding to the apical pole of the intestinal epithelium, comprises a coculture of Caco-2 cells differentiated into enterocytes and HT29-MTX cells differentiated into goblet cells. The second compartment, corresponding to the basolateral pole of the intestinal epithelium, comprises a culture of THP-1 monocytic cells differentiated into macrophages.The model according to the present invention is characterized in that the cells contained in the first compartment produce interleukin (IL-6) at a concentration greater than 100 pg / mL, and interleukin 8 (IL-8) at a concentration greater than 150 pg / mL, and the cells contained in the second compartment produce tumor necrosis factor α (TNF-α) at ​​a concentration greater than 40 pg / mL and interleukin 1β (IL-1β) at a concentration greater than 90 pg / mL. The present invention also relates to the method for obtaining this model as well as to a method for selecting candidate compounds for the treatment of inflammatory bowel diseases by verifying their ability to stop inflammation upon increase in permeability or to verify the restoration of permeability and the mucus layer.

The present invention discloses a method for constructing an animal model of ankylosing spondylitis and chronic enteritis. By using proteoglycan PG immune induction and sodium dextran sulfate chemical induction methods, an animal model is established that simulates the coexistence of ankylosing spondylitis and chronic enteritis in terms of symptoms, imaging changes, and pathological characteristics. The model mice exhibit imaging changes similar to those of human ankylosing spondylitis, such as sacroiliac joint bone erosion and sclerosis, narrowing and roughening of the joint space, and worm-eaten changes. Furthermore, they exhibit pathological changes similar to those of human chronic enteritis, such as intestinal epithelial cell destruction, glandular disorder, crypt structure destruction, goblet cell reduction, and inflammatory cell infiltration. This model can be used to study the interaction mechanism between the two diseases, explore new therapeutic targets, and help evaluate the potential application of new drugs in the treatment of ankylosing spondylitis and chronic enteritis, providing an important tool for mechanism research and drug development of such co-morbidities.

Systems and methods involve abrading a patient lung airway wall to reduce mucus production therein. Exemplary techniques include rotationally and / or linearly oscillating an abrasive material against the airway wall so as to damage mucus producing tissues, for example by removing goblet cells, while destroying less than the entire airway wall. The abrasive material may be present on the surface of an expandable balloon body or another expandable device, which can be delivered to the patient treatment site via a bronchoscope. In some cases, the abrasion techniques can cause cell damage or death at a controlled or predetermined tissue depth.

The application is a divisional application of 2025116336025, the invention provides an application of 2, 4-dihydroxy-6-methoxyacetophenone in preparation of a medicine for treating lacrimal gland secretion dysfunction related diseases, a lacrimal gland dysfunction dry eye mouse model is constructed in the application, and liposome entrapped 2, 4-dihydroxy-6-methoxyacetophenone is adopted for intervention, so that the medicine for treating lacrimal gland secretion dysfunction related diseases is obtained. Experimental results show that the ocular surface function and structure of a model animal are remarkably improved through treatment of 2, 4-dihydroxy-6-methoxyacetophenone, the cornea sodium fluorescein staining score of a mouse in a 2, 4-dihydroxy-6-methoxyacetophenone treatment group is remarkably reduced, and cornea epithelium injury is effectively repaired; the epithelial structure in the cornea tissue tends to be complete, and inflammatory cell infiltration of a matrix layer is obviously relieved; the density of goblet cells in the conjunctiva is obviously increased, which indicates that the secretion function of the mucous layer on the ocular surface is recovered. The treatment of 2, 4-dihydroxy-6-methoxyacetophenone has an improvement trend on tear film rupture time and tear secretion amount, which indicates that the 2, 4-dihydroxy-6-methoxyacetophenone has a potential effect in the aspects of maintaining tear film stability and promoting basic tear secretion.

Apparatuses, systems and methods are provided for treating pulmonary tissues via delivery of energy, generally characterized by high voltage pulses, to target tissue using a pulmonary tissue modification system (e.g., an energy delivery catheter system). Example pulmonary tissues include, without limitation, the epithelium (the goblet cells, ciliated pseudostratified columnar epithelial cells, and basal cells), lamina propria, submucosa, submucosal glands, basement membrane, smooth muscle, cartilage, nerves, pathogens resident near or within the tissue, or a combination of any of these. The system may be used to treat a variety of pulmonary diseases or disorders such as or associated with COPD (e.g., chronic bronchitis, emphysema), asthma, interstitial pulmonary fibrosis, cystic fibrosis, bronchiectasis, primary ciliary dyskinesia (PCD), acute bronchitis and / or other pulmonary diseases or disorders.

The invention belongs to the technical field of medicine preparation, and provides an ophthalmic external preparation and a preparation method thereof. According to the ophthalmic external preparation, curcumin included by hydroxypropyl-beta-cyclodextrin loaded on exosome modified by polylysine is adopted as an effective component. The preparation can improve the drug concentration of cornea tissues and realize accurate delivery of ocular surfaces; meanwhile, the exosome and curcumin form a synergistic effect, so that the release of proinflammatory factors such as IL-1beta and TNF-alpha can be inhibited, the secretion of goblet cell mucoprotein and the proliferation of corneal epithelial cells can be promoted, and the tear film rupture time is prolonged; in addition, the preparation is excellent in biocompatibility, free of ocular surface stimulation reaction and high in safety.

The application belongs to the field of biological medicine, and particularly relates to application of DJ-1 in treatment and diagnosis of bronchial asthma. DJ-1 is used as a target in preparation or screening of drugs for bronchial asthma or allergic inflammation; a drug for treating hyperplasia of goblet cells and mucus metaplasia in bronchial asthma, and an animal model for studying inhibition of differentiation of goblet cells and mucus metaplasia. The application identifies, for the first time, an important role of a signal pathway DJ-1 / Ltc4s, which has not been found in eosinophils and lung epithelial cells before, in differentiation of secretory cells into goblet cells, and finds, for the first time, an inhibitory effect of inhibition of the DJ-1 / Ltc4s signal pathway on differentiation of goblet cells in lung epithelial cells through a large number of studies.

The invention discloses a pig jejunum crypt separation and organoid model construction method, and belongs to the technical field of animal tissue separation and culture. The method specifically comprises the following steps: intestinal tract collection, cleaning solution preparation, intestinal tract treatment, tissue trimming, tissue cleaning, digestive juice preparation, tissue digestion, cell mass separation, crypt separation, crypt counting, crypt collection, crypt inoculation and organoid culture. The porcine jejunum organ obtained by the method has a typical three-dimensional cystic structure, has complete epithelial polar and functional cell types, including microvillus, goblet cells, panning cells and endocrine cells, and shows good barrier function and drug metabolic activity. A reliable in-vitro model platform is provided for pig intestinal development, nutrient absorption, pathogen infection mechanism research and precision medical treatment, meanwhile, a technical foundation is laid for large-scale application of organoids, and the method has important scientific significance and clinical value.

The invention discloses an application of a valeriana jatamansi jones extract in preparation of a medicine for treating and preventing colitis, and provides an application of the valeriana jatamansi jones extract in preparation of a medicine for treating and preventing colitis, which discovers that the valeriana jatamansi jones extract can improve the intestinal function of a mouse with colitis and has an anti-colitis effect. The valeriana jatamansi jones extract with increased dosage increases the number of goblet cells of mice, improves the distribution of mucoprotein, and improves the damage condition of the intestinal mucous layer of the mice with colitis.

The invention discloses an application of Allobacter stercolicis AS, an aquatic feed and a fish culture method, and relates to the technical field of feeds, in particular to the application of the Allobacter stercolicis AS as well as the aquatic feed and the fish culture method. The Alobacter faecalis AS can be used for preparing aquatic feed, the Alobacter faecalis AS is purchased from Leibniz Instrument DSMZ, and the serial number of the Alobacter faecalis AS is DSM 13633. The Alobacter faecalis AS can be used for preparing aquatic feed, and the Alobacter faecalis AS can be used for preparing aquatic feed. The heterobacter faecalis AS is added into the fish culture feed, so that the intestinal barrier health of fishes can be improved, and the number of goblet cells can be increased; meanwhile, the fish with the heterobacter faecalis can also reduce liver injury and reduce the content of cholesterol and free fatty acid in serum and liver; besides, by inhibiting expression of proinflammatory factors and improving expression of anti-inflammatory factors, resistance of fishes to aeromonas hydrophila is improved, and survival rate of fishes is increased.

The invention discloses application of a bifidobacterium longum subsp. Infantis CCFM1426 strain and vitamin A in preparation of a medicine for improving the physiological activity of the vitamin A and / or relieving colitis and / or xerophthalmia symptoms. The probiotic agent provided by the invention comprises a bifidobacterium longum subsp. Infantis CCFM1426 strain with the preservation number of GDMCC No.65152 and vitamin A, and can be used for improving the retinoic acid level in the colon of a mouse with ulcerative colitis; the diamine oxidase level, the intestinal fatty acid binding protein level and the lipopolysaccharide binding level in serum of mice with ulcerative colitis are reduced; the corneal injury, basal vacuolation and conjunctival goblet cell injury of the xerophthalmia mice are relieved; the level of retinoic acid in serum of the dry-eye mouse is improved; and the levels of IL-6, IL-17 and TNF-alpha in serum of dry eye mice are reduced. Therefore, the probiotic agent disclosed by the invention has a relatively great application prospect in preparation of products for supplementing vitamin A and preventing and / or treating ulcerative colitis and xerophthalmia.

This invention discloses an oral frameshift peptide neoantigen vaccine, its preparation method, and its application, relating to the field of biomedical technology. The preparation method includes: 1) synthesizing a sea urchin-like metal-organic framework (MOF) via a hydrothermal method using zinc ions and 3,3''-dihydroxy-2',5'-dimethyl-[1,1':4',1''-terphenyl]-4,4''-dicarboxylic acid; 2) loading the sea urchin-like MOF with a frameshift peptide and a Toll-like receptor 9 agonist via electrostatic interactions and / or van der Waals forces to prepare the oral frameshift peptide neoantigen vaccine. This vaccine not only promotes antigen endocytosis and transcytosis via intestinal microfold cells by activating cyclin 42, but also alleviates immune tolerance mediated by the goblet cell-regulatory T cell immunosuppressive axis and activates specific CD8+. + T cells help prevent the development of Lynch syndrome-related colorectal cancer.

The application discloses a lactobacillus taiwanensis with enhanced intestinal barrier function and application thereof, and belongs to the technical field of microorganisms and medicine. The lactobacillus taiwanensis is preserved in the Guangdong Microbial Culture Collection Center, and the preservation number is GDMCC No.63714. The intestinal barrier enhancement and protection of the lactobacillus taiwanensis CCFM1318 are embodied in the following aspects: (1) the lactobacillus taiwanensis CCFM1318 has good in-vitro gastrointestinal tolerance, strong adhesion to intestinal epithelial cells and strong colonization in the gastrointestinal tract; (2) the lactobacillus taiwanensis CCFM1318 significantly up-regulates the expression level of tight junction protein related genes in Caco-2 cells after DSS stimulation; (3) the bacterial-free culture medium supernatant of the lactobacillus taiwanensis CCFM1318 can promote the expression and secretion of MUC2 of the LS 174T goblet cell line, and can improve the expression of MUC2 after endoplasmic reticulum stress, thereby enhancing and protecting the intestinal barrier. The lactobacillus taiwanensis CCFM1318 has great application prospect in products (such as food or medicine) for enhancing and protecting the intestinal barrier.

This application belongs to the technical field of health foods, and particularly relates to a plum exosome, a preparation method thereof, and an application in the preparation of a product for relieving constipation. The preparation method of a plum exosome provided by this application deeply processes plums, extracts plum exosomes from plums, uses the miRNA nucleic acids contained in the plum exosomes to promote the expression of mucin genes in goblet cells and the proliferation of beneficial bacteria such as Bifidobacterium and Lactobacillus, and uses the antioxidant activity of the plum exosomes to reduce the adverse effects of oxidative stress on intestinal cells and the microbial community, achieving the effect of relieving constipation, thereby solving the technical problem of the lack of deep processing research on plums in the prior art.

The invention discloses application of oxidized berberine and neohesperidin in improving intestinal health of broiler chickens, and belongs to the technical field of feed additives. Research finds that oxidized berberine and neohesperidin can increase the intestinal villus height, crypt depth and goblet cell number of broiler chickens and improve intestinal health; the slaughter indexes such as daily weight gain and feed intake can be improved, the feed-weight ratio is reduced, and the slaughter indexes such as carcass weight and semi-eviscerating weight are increased; meanwhile, the serum immune factor and antioxidant index level is improved, the safety is high, and no obvious toxicity exists; and the two components are combined for use, so that a synergistic interaction effect is also achieved. The invention provides a new raw material resource for improving the intestinal health of the broiler chicken and improving the production performance and economic value of the broiler chicken.

The invention provides a donkey milk exosome preparation, a preparation method and application, and belongs to the technical field of life sciences, the donkey milk exosome preparation comprises a donkey milk exosome and a complex microbial inoculant; wherein the complex microbial inoculant is prepared from clostridium butyricum, bacillus subtilis and enterococcus faecium. The scheme that the donkey milk exosome and the complex microbial inoculant are compounded for use is created for the first time, and the donkey milk exosome and the complex microbial inoculant can achieve synergistic interaction, so that inflammatory factors can be effectively reduced, the number of goblet cells is increased, and the intestinal mucosa is repaired; meanwhile, by utilizing the natural anti-inflammatory property of the donkey milk exosome and the micro-ecological regulation of the complex microbial inoculant, the side effects of chemical drugs are avoided, and an integrated scheme of'intestinal barrier repair-immune regulation 'is provided.

The invention provides a preparation process of black chickpea sprout peptide, the sprout peptide and application. The germinated peptide prepared by the invention is prepared by the following steps: germinating black chickpeas until the length is 0.8-1.2 cm, and hydrolyzing the germinated black chickpeas with a composite biological enzyme. Aiming at the characteristics of black chickpeas, the method comprises the following steps: 1, carrying out pretreatment before germination so as to remove tannic acid; 2, a relatively high constant germination temperature is adopted in the germination stage; 3, a crushing mode of a high-shear dispersion machine at the speed of 10000 rpm is adopted; 4, the ultrafiltration interception is 10kDa. The application of the black chickpea sprout peptide in preparation of the health-care medicine for assisting in protecting gastrointestinal mucosa injury specifically shows that the number of neutrophils in the intestinal tract is reduced, the area of the small intestine cavity is reduced, and the number of goblet cells in the intestinal tract is increased.

Systems and methods involve abrading a patient lung airway wall to reduce mucus production therein. Exemplary techniques include rotationally and / or linearly oscillating an abrasive material against the airway wall so as to damage mucus producing tissues, for example by removing goblet cells, while destroying less than the entire airway wall. The abrasive material may be present on the surface of an expandable balloon body or another expandable device, which can be delivered to the patient treatment site via a bronchoscope. In some cases, the abrasion techniques can cause cell damage or death at a controlled or predetermined tissue depth.

The invention discloses bifidobacterium breve for regulating metabolism of vitamin A in intestinal flora and application of the bifidobacterium breve, and belongs to the field of microorganisms. According to the bifidobacterium breve CCFM1489 disclosed by the invention, vitamin A can be subjected to external metabolism to generate retinoic acid; corneal injury and conjunctival goblet cell injury of mice with xerophthalmia are relieved; the RA level in serum of the dry-eye mouse is improved; the levels of IL-6, IL-17 and TNF-alpha in serum of the mouse with the dry eye syndrome are reduced, the intestinal flora of the mouse with the dry eye syndrome is regulated, and the abundance of beneficial bacteria is increased. Therefore, the bifidobacterium breve CCFM1489 has a huge application prospect in preparation of products for preventing and / or relieving xerophthalmia.

The application discloses a prillium fimicola for relieving ulcerative colitis and application thereof, and belongs to the technical field of microorganisms. The prillium fimicola N03 can improve body weight loss and disease activity index increase caused by ulcerative colitis, inhibit colon atrophy, protect the integrity of colon tissue structure, increase the number of goblet cells, reduce the inflammation level in the intestinal tract, can significantly up-regulate the expression of Nrf2 , Gpx2 and Nqo1 in the body of a mouse with colitis, effectively improve the impaired activation of Nrf2 signal pathway in the body of the mouse, and has a good relieving effect on colitis. The prillium fimicola N03 has a very wide application prospect when used for preparing a medicine composition for relieving ulcerative colitis and a fermented food.​​​​​​​​

The invention discloses an indole derivative for promoting development of piglet intestinal stem cells, and particularly relates to application of indole-3-aldehyde in promoting development and growth performance of piglet intestinal epithelium. The indole-3-aldehyde can be used as a feed additive to be applied to a piglet creep feed and a nursing feed, promote the development of forms and functions of piglet intestinal stem cells and intestinal epithelium, improve the length and the index of the small intestine of the piglet and reduce the feed-weight ratio of the piglet. It is found that indole-3-aldehyde guarantees animal health and improves the growth performance of animals by adjusting proliferation and differentiation of piglet intestinal stem cells, increasing the number of goblet cells, up-regulating expression of tight junction protein, promoting intestinal epithelium development and intestinal barrier functions and promoting absorption and utilization of intestinal epithelium to nutrient substances.

This invention relates to the fields of biomedicine and food nutrition, specifically to the application of purple sweet potato anthocyanins in the preparation of products for preventing or improving intestinal aging. This invention demonstrates that purple sweet potato anthocyanins can significantly improve the degenerative changes and barrier fragility of the colon caused by natural aging, restore colonic crypt morphology and epithelial ultrastructure, and upregulate the expression of tight junction proteins and mucus barrier-related indicators. Furthermore, purple sweet potato anthocyanins can effectively enhance crypt proliferation activity and promote the differentiation of intestinal stem cells into secretory lineages (such as goblet cells and enteroendocrine cells). Its mechanism of action does not rely on direct anti-inflammatory pathways, but rather on remodeling intestinal flora metabolism (such as increasing short-chain fatty acids) and activating intestinal cell autophagy via the PI3K-Akt signaling pathway, thereby supporting the continuous renewal and maintenance of the intestinal barrier. This invention provides a new approach for the development and application of food-derived polyphenols targeting the gut to promote healthy aging.